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Despite several investigations, the transcriptional mecha-
nisms that regulate the expression of both type I collagen genes
(COL1A1 and COL1A2) in either physiological or pathological
situations, such as scleroderma, are not completely known. We
have investigated the role of hc-Krox transcription factor on
type I collagen expression by human dermal fibroblasts.
hc-Krox exerted a stimulating effect on type I collagen protein
synthesis and enhanced the corresponding mRNA steady-state
levels ofCOL1A1 andCOL1A2 in foreskin fibroblasts (FF), adult
normal fibroblasts (ANF), and scleroderma fibroblasts (SF).
Forced hc-Krox expression was found to up-regulate COL1A1
transcription througha112/61-bp sequence inFF,ANF, and
SF. Knockdown of hc-Krox by short interfering RNA and decoy
strategies confirmed the transactivating effect of hc-Krox and
decreased substantiallyCOL1A1 transcription levels in all fibro-
blast types. The112/61-bp sequence bound specifically hc-
Krox but also Sp1 and CBF. Attempts to elucidate the potential
interactions between hc-Krox, Sp1, and Sp3 revealed that all of
them co-immunoprecipitate from FF cellular extracts when a
c-Krox antibody was used and bind to the COL1A1 promoter in
chromatin immunoprecipitation assays. Moreover, hc-Krox
DNA binding activity to its COL1A1-responsive element is
increased in SF, cells producing higher amounts of type I colla-
gen compared with ANF and FF. These data suggest that the
regulation of COL1A1 gene transcription in human dermal
fibroblasts involves a complexmachinery that implicates at least
three transcription proteins, hc-Krox, Sp1, and Sp3, which
could act in concert to up-regulate COL1A1 transcriptional
activity and provide evidence for a pro-fibrotic role of hc-Krox.
Fibroblasts represent themain cellular population of dermis.
Their principal function is to maintain the extracellular matrix
(ECM)5 homeostasis. A complex network of cytokines/growth
factors, acting by autocrine and paracrine mechanisms, con-
trols the fibroblast metabolism and ensures the tissue integrity.
In a normal situation, there is a balance between synthesis and
degradation of the matrix components, including elastic fibers,
proteoglycans, and collagens (1, 2). This equilibrium is dis-
rupted in pathological processes, such as fibrosis, and charac-
terized by excessive production of matrix proteins, particularly
of type I collagen, which is the major structural component of
dermal ECM (2).
Type I collagen is composed of two 1 chains and one 2
chain, encoded by two distinct genes, COL1A1 and COL1A2,
respectively (3). Coordinated transcription of these genes
involves similar cis elements interacting with the same tran-
scription factors, such as Sp1, Sp3, CBF (CCAAT-binding fac-
tor), and c-Krox (collagen-Kru¨ppel box) (4–15). The relative
proportions and/or interactions between these and other tran-
scription factors are responsible for the modulation of type I
collagen expression under physiopathological conditions.
Human c-Krox (hc-Krox) is a zinc finger transcription factor
belonging to the Krox family proteins and binds to GC-rich
sequences. This protein harbors a BTB-POZ (for “broad com-
plex, tramtrack, and bric a` brac/pox virus and zinc finger”)
domain in its N-terminal extremity, which is responsible for
protein homo- and heterodimerization and for the inhibition of
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transcriptional activity of ECM-targeted genes (16). hc-Krox
has already been found to inhibit type I collagen (COL1A1 and
COL1A2), fibronectin, and elastin genes in fibroblastic cells and
uridine diphosphoglucose dehydrogenase (UGDH) in rabbit
articular chondrocytes (17, 18).
On the other hand, the murine homologue of hc-Krox,
mouse c-Krox (mc-Krox), was first cloned as a partial cDNA
lacking the BTB-POZ domain and was demonstrated to be an
activator of transcription of mouseCol1a1 andCol1a2 genes in
fibroblastic cells (14). This transcription factor is expressed in a
quite specific manner in the dermis, although it is absent in
bone (14, 15). Its expression can be detected at 9.5 days post-
coitum in the myodermatomes and it precedes type I collagen
expression. These data, reporting the co-localization of type I
collagen and c-Krox expression in skin fibroblasts, suggest the
possible involvement of the trans factor in the fibrotic process,
particularly in scleroderma. Further support to this hypothesis
comes from the fact that the full-length mc-Krox (containing
the BTB-POZ domain) was recently found to promote thymo-
cyte differentiation intoCD4Tcells rather than intoCD8T
cells (19, 20). Knowing that during the early stages of sclero-
derma disease there is an activation of CD4 T cells, rather
than of CD8T cells (21), wemay suppose that c-Krox plays an
important role in the early manifestation of this disease that
leads to fibrotic reaction in later stages.
Sp1 and Sp3 are ubiquitous proteins belonging to the family
of Sp transcription factors recognizing GC and TC boxes, like
c-Krox (22). Sp1 is a well characterized activator of type I col-
lagen genes (6, 12, 23–25); however, its function seems to
depend on the cellular and/or molecular context. It has been
shown to inhibit mouse Col1a1 gene in NIH-3T3 fibroblasts
(26) and to function as a co-inhibitor of human COL1A2 gene
transcription when it interacts with the transcription factor
Fli-1 in human skin fibroblasts (27). Additionally, Sp1may play
a role in fibrotic diseases, because it is one of the mediators of
transforming growth factor-1, a profibrogenic factor that acti-
vates human COL1A1 gene transcription (10, 22, 28). In this
regard, its binding activity is increased in human scleroderma
fibroblasts and in hepatic stellate cells, compared with normal
cells (23, 29).
Sp3 shares identical binding sites and affinities with Sp1.
Consequently, it often behaves like an Sp1 antagonist in many
systems, competing with the latter for the same DNA sites,
reducing Sp1 binding activity, and inducing inhibition of gene
transcription (30–33). Moreover, Sp3 on its own exerts bifunc-
tional effects on gene transcription. These effects can be cell-
and/or promoter-specific, but it can also depend on the number
of binding sites available for Sp3 on a given gene (34–35).
Recent findings show that there exist four Sp3 isoforms, result-
ing from alternative translational start sites. Thus, Sp3 does not
appear as a simple Sp1 homologue but is rather controlled by
complex mechanisms of expression (36).
In this study, we investigated the functions of hc-Krox in
human dermal fibroblasts. We found that hc-Krox increases
type I collagen synthesis in human foreskin fibroblasts (FF)
obtained from young children, adult normal fibroblasts (ANF),
and scleroderma fibroblasts (SF). Moreover, hc-Krox enhances
human COL1A1 transcriptional activity in FF, ANF, and SF
through a 112/61-bp promoter sequence. The factor can
bind to this promoter region in vitro and in vivo, as well as Sp1
and CBF.
Our results reveal for the first time the transactivating role of
hc-Krox on human COL1A1 gene in normal and pathological
human dermal fibroblasts and provide evidence for interac-
tions between hc-Krox, Sp1, and Sp3. Moreover, the data sug-
gest that hc-Krox is a pro-fibrogenic factor, because its DNA
binding is increased in SF compared with ANF, and this is cor-
relatedwith enhanced type I collagen expression, and this offers
new perspectives for therapeutic strategies that could be
applied to fibrotic diseases and aging-related skin disorders.
EXPERIMENTAL PROCEDURES
Cell Cultures—Children foreskin samples were provided by
Dr. P. Ravasse (Dept. of Children Surgery, CaenHospital, Caen,
France).HumanANFand SFwere obtained from forearmbiop-
sies of either healthy donors or patients suffering from localized
scleroderma (Prof. F.-X. Maquart, Laboratory of Medical Bio-
chemistry and Molecular Biology, Reims, France). Fibroblasts
were obtained after explant cultures and seeded at 2.5  106
cells/cm2 in 175-cm2 flasks, in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum, glutamine (2
mM), penicillin (100 IU/ml), streptomycin (100 g/ml), and
fungizone (0.25 g/ml) in a 5% CO2 environment. They were
passaged with a trypsin (0.05%), EDTA (0.25 mM) solution
(Invitrogen) after reaching confluency. All the experiments
were performed on cells between 5 and 9 passages.
Collagen Labeling and Assay—Fibroblasts were seeded at
0.17 105 cells/9.6-cm2 wells, in 10% fetal calf serum-contain-
ing Dulbecco’s modified Eagle’s medium, and transiently trans-
fected, or not, by the calcium phosphate precipitation method
with the hc-Krox expression vector and/or the corresponding
insertless plasmid (pSG5/hc-Krox). After 15 h, the culture
mediumwas replaced by the same freshmedium supplemented
with -aminopropionitrile (50 g/ml) and ascorbic acid (50
g/ml) for a further 24-h period. The same medium was then
renewed, and [3H]proline (2 Ci/ml) (PerkinElmer Life Sci-
ences) was added. After 24 h, the culturemediumwas collected,
and the labeled collagen was assayed, using the bacterial colla-
genasemethod (37). The cell layerwas scraped, and the extracts
were sonicated. They were used to assay cell protein levels,
using the Bradford colorimetric assay. Levels of collagen and
noncollagenous proteins were corrected for total protein
amount.
An alternative method of transfection was also used to esti-
mate collagen neosynthesis in the siRNA knockdown experi-
ments. Fibroblasts were trypsinized at confluency and then dis-
tributed in Eppendorf tubes (1  106 cells per 1.5-ml tube).
Cells were centrifuged for 10 min at 200  g and transfected
using the Nucleofector apparatus (AMAXA, Ko¨ln, Germany),
according to the manufacturer’s instructions. After the trans-
fection of hc-Krox siRNA (1g), the cells were plated and incu-
bated in the samemedia, and the bacterial collagenase assaywas
performed as described above.
Site-directedMutagenesis—Mutant collagen promoters were
made using the 804hCOL-LUC as a template for PCR
together with mutated oligonucleotides as follows. A 30-mer
hc-Krox Role in HumanDermal Fibroblasts
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spanning the collagen promoter sequence from 84 to 55
was synthesized containing eitherG toTmutations at positions
61 and 62 or C to A mutations at positions 73 and 74.
PCR was performed with a single oligonucleotide primer and
the 804hCOL-LUC template for 18 cycles using Pfu Turbo
polymerase (Stratagene) as directed by the manufacturer. The
PCR product was digested with DpnI restriction endonuclease
to eliminate the input template, followed by transformation of
Escherichia coli. Plasmid DNA extracted from bacterial colo-
nies was sequenced using the pGL2 primer (Promega) to con-
firm the presence of the desiredmutations. This gave rise to the
804mut73/74 and 804mut61/62 constructs. The
112 mutant constructs were created by using the 804
mutant constructs as PCR templates with an upstream 18-mer
beginning at 112, and the pGL2 as downstream primer. All
plasmids were sequenced prior to transfection to confirm the
presence of the correct mutations and the promoter length.
Transient Transfections with COL1A1 Constructs—Fibro-
blasts were passaged after reaching confluency and then dis-
tributed in Eppendorf tubes (1  106 cells per 1.5-ml tube).
Cells were centrifuged for 10 min at 200  g and transfected
using the Nucleofector apparatus and an NHDF kit (AMAXA,
Ko¨ln, Germany), according to the manufacturer’s instructions.
For each sample, 2g of pSV40/-gal expression vector, 2g of
reporter plasmids, and 1 g of hc-Krox expression vector were
used. After transfection, cells were seeded in 9.6-cm2 wells and
incubated 12 h at 37 °C. The medium was then replaced, and
cells were harvested 6 h later to determine luciferase and -ga-
lactosidase activities, as well as the protein amount (38).
The other human COL1A1 plasmid constructs were
described previously (39). pK1A4 Luc and pK1A4mut Luc plas-
mids were described previously (14).
siRNA Experiments—The following siRNA sequences have
been designed by Qiagen (Courtaboeuf, France): hc-Krox
siRNA forward, r(UCGCUGCUUGCAUGGAGAU)dTdT, and
reverse, r(AUCUCCAUGCAAGCAGCGA)dTdG; control
siRNA forward, r(UUCUCCGAACGUGUCACGU)dTdT, and
reverse, r(UUCUCCGAACGUGUCACGU)dTdT.
FF, ANF, and SF were transfected as described earlier, with
the following modifications. For each sample of 1 106 cells, 1
or 1.5g of hc-Krox siRNAor control siRNAwere added to the
transfection mixture. 12 h after transfection, the medium was
replaced with fresh medium, and 6 h later, cells were harvested
tomeasure the transcriptional activity or to extract total RNAs.
RNA Extraction and Real Time RT-PCR Analysis—Fibro-
blasts were seeded in 9.6- or 55-cm2 wells and transiently
transfected by the AMAXA Nucleofector apparatus or the
calcium phosphate precipitationmethod, respectively, in the
presence of the hc-Krox expression vector (pSG5/hc-Krox)
and/or the corresponding insertless plasmid (pSG5). 12 h
after Nucleofector transfection, and 17 h after transfection
by the calcium phosphate precipitation procedure, the
medium was replaced by fresh medium. 6 h (nucleofection
procedure) or 24 h (calcium phosphate precipitation) later,
cells were harvested. Total RNA were extracted (40), and 2
g were reverse-transcribed and analyzed (18). Real time
RT-PCRs were performed (18), using sequence-specific
primers (Table 1) (Eurogentec, Angers, France) defined with
the “Primer Express” software (Applied Biosystems, Court-
abœuf, France). Analysis of relative gene expression was
done by using the 2Ct method (41).
Nuclear Extracts and Gel Retardation Assays—Nuclear
extracts were prepared using a mini-preparation procedure
(42), and gel retardation assays were performed with the
oligonucleotides shown in Table 2 or in Fig. 5A. The probes
were end-labeled with [-32P]dATP (PerkinElmer Life Sci-
ences) using T4 polynucleotide kinase (Promega, Charbon-
nie`res, France). FF, ANF, and SF nuclear extracts (5 or 7.5
g) were incubated for 10 min at room temperature with the
probe (5 fmol) in 20 l of a specific binding buffer (43) and in
the presence of 1 g of poly(dI-dC)poly(dI-dC) (Amersham
Biosciences, Orsay, France), used as a DNA nonspecific com-
petitor. For antibody interference reactions, nuclear extracts
were incubated with specific antibodies directed against
c-Krox (antibody developed in collaboration between our
laboratory and Novotec (Lyon, France)), Sp1, Sp3, and CBFb
(Tebu-Bio SA, Le Perray en Yvelines, France) for 10 min at
room temperature and then 10min at 4 °C. Finally, the probe
was added, and a 10-min incubation at room temperature
was performed. Samples were then fractionated by electro-
phoresis for 1.5 h at 150 V on a 5% polyacrylamide gel (acryl-
amide/bisacrylamide at 30:1) in 0.5 TBE (45 mM Tris
borate, 1 mM Na2EDTA) and visualized by autoradiography.
Western Blot Analysis—Fibroblasts were seeded in 55-cm2
wells and at 90% confluency, transiently transfected by the
calcium phosphate precipitation method in the presence of
an expression vector containing or not the hc-Krox cDNA.
17 h after transfection, the medium was replaced by fresh
medium and 24 h later, cells were harvested, and cellular
extracts were prepared as described previously (18). The cel-
lular proteins were fractionated on an 8% polyacrylamide gel
TABLE 1
Primers used in real time RT-PCR experiments (Eurogentec)
Gene of interest Forward primer (orientation 53 3) Reverse primer (orientation 53 3)
COL1A1 CACCAATCACCTGCGGTACAGAA CAGATCACGTCATCGCACAAC
COL1A2 AAAACATCCCAGCCAAGAACTG AAACTGGCTGCCAGCATTG
hc-Krox AGGGTTCTGGAAGATGAAATGAGT AAGAGGACCAACTTTAGCCAATACTT
COL3A1 TCTTGGTCAGTCCTATGCGGATA CATCGCAGAGAACGGATCCT
ARNr 18 S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT
TABLE 2
Oligonucleotides used in this study (Eurogentec)
Oligonucleotide
name
Sequence (potential binding sites for
CBF, Sp1/Sp3, and c-Krox transcription
factors are in boldface)
SOX9 (“decoy” control) 5-AGCCCCATTCATGAGAGACGAGGT-3
112/61 wild type 5-AGGCAGCTCTGATTGGCTGGGGCACGGGCGG
CCGGCTCCCCCTCTCCGAGGG-3
A1(I) wild type 5-CTTGCGGGAGGGGGGGCGCTGGGTGGACA-3
hc-Krox Role in HumanDermal Fibroblasts
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(acrylamide/bisacrylamide at 30:1) and electrotransferred
on a polyvinylidene difluoride membrane (PerkinElmer Life
Sciences). After blocking with TBST (TBS, 0.1% Tween 20)
containing 10% nonfat dry milk, membranes were incubated
with primary antibodies (rabbit anti-human type I collagen,
dilution 1:1500 (Novotec, Lyon, France), or mouse anti-hu-
man -actin, dilution 1:500 (Tebu-Bio)) in TBST, 2% nonfat
dry milk. Membranes were then
rinsed with TBST and incubated
with secondary antibodies (horse-
radish peroxidase-conjugated goat
anti-rabbit or anti-mouse anti-
body) (Tebu-Bio). Type I collagen
and -actin protein bands were
revealed using a Western blot
detection kit (WestPico kit,
Pierce) and quantified with Adobe
Photoshop 7.0.
Immunoprecipitation Assays—10
l of antibody raised against c-Krox
were incubated with 40 l of anti-
rabbit IgG conjugated to agarose
beads (Sigma) in cold 1 phos-
phate-buffered saline for 2 h at 4 °C.
The samples were then centrifuged
for 15 s at 1200 rpm at 4 °C. The
supernatants were discarded, and
the pellets were rinsed twice with
RIPA buffer (1% IGEPAL CA-630,
1% (w/v) sodium deoxycholate
monohydrate, 0.1% SDS, 0.15 M
NaCl, 40 g/ml aprotinin). Cellular
extracts (corresponding to 2–3 
106 FF) were added to the sub-
strates, incubated for 2 h at 4 °C, and
centrifuged for 15 s at 1200 rpm.
Supernatants were removed, and
pellets were rinsed four times with
an IP buffer (0.05 M Tris-HCl, pH
7.4, 0.1%TritonX-100, 0.15MNaCl)
and once with cold phosphate-buff-
ered saline. Then 20 l of 2 sam-
ple buffer were added to each
immunoprecipitation reaction, and
samples were denatured at 95 °C for
5 min and submitted to Western
blot assays as described above. Pri-
mary antibodies against Sp1 (rabbit
anti-human Sp1, 1:300 dilution in
TBST, 2% nonfat milk) and Sp3
(rabbit anti-human Sp3, 1:300 dilu-
tion in TBST, 2% nonfat milk) were
purchased from Tebu-Bio. c-Krox
antibody (rabbit anti-mouse c-Krox)
was used at a dilution of 1:250 in
TBST, 5% nonfat milk.
Glutaraldehyde Cross-linking Ex-
periments—10 g of nuclear extracts
were incubated in the presence of 2l of 0.1% glutaraldehyde or
not, in a protein binding buffer (43) for 10min at room temper-
ature. Then 5l of 5 sample buffer were added, samples were
denaturated for 5 min at 95 °C and subjected to Western blot
assays as described previously.
Chromatin Immunoprecipitation Assay—Chromatin immu-
noprecipitation assayswere performed by using a commercially
FIGURE1.hc-Krox increases type I collagen synthesis andCOL1A1andCOL1A2mRNAsteady-state levels
inFF.A,FFwere transiently transfectedby the calciumphosphate co-precipitationmethodwith1, 5, and15g
of pSG5/hc-Krox expression vector. For each amount of hc-Krox transfected, the insertless pSG5 vector was
used as a complement to 15 g, to transfect each sample with the same amount of DNA. 15 h later, the cell
culturemediumwas changed, andabacterial collagenaseassaywas realizedasdescribedunder “Experimental
Procedures.” The values, normalized to total protein amount, are expressed as counts/min/g of protein and
represent themeans S.D. of triplicate dishes. B, FFwere transfected as inA, with a total amount of DNAequal
to 20 g; total proteins were extracted and used in Western blotting experiments as described under “Exper-
imental Procedures” to detect type I procollagen and -actin using specific antibodies. The histograms repre-
sent the relative expression of type I collagen versus -actin, estimated after densitometric analysis of the
electrophoregram.C, FFwere transiently transfectedusing theAMAXANucleofectorwith 0.1 or 0.5gof pSG5
containing or not the hc-Krox cDNA. 18 h after transfection, total RNAs were extracted, and 1 g was reverse-
transcribed into cDNA. 2l of cDNAswerediluted100 times andused in real timePCR toamplifyCOL1A1 (panel
i), COL1A2 (panel ii), hc-Krox (panel iii), and 18 S cDNAs, with specific forward and reverse primers. COL1A1,
COL1A2, and hc-KroxmRNAs relative expressionwas normalized to 18 S rRNA according to 2Ctmethod (A.U.,
arbitrary units).
hc-Krox Role in HumanDermal Fibroblasts
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available chromatin immunoprecipitation kit (Active Motif).
Briefly, fibroblasts (10 150-cm2 flasks) were cross-linked,
scraped, and lysed according to the manufacturer’s instruc-
tions. The DNAwas then sheared using enzymatic digestion,
and specific protein-DNA complexes were immunoprecipi-
tated using either anti-hc-Krox, anti-Sp1, or anti-Sp3 anti-
bodies. Following overnight immunoprecipitation, cross-
linking was reversed, and the proteins were removed after
treatment with proteinase K, and the DNA was purified and
used as a template in PCR assay. The primers used for the
amplification of the COL1A1 promoter were as follows: for-
ward, 5-CAGAGCTGCGAAGAGGGGA-3, and reverse,
5-AGACTCTTTGTGGCTGGGGAG-3. The amplicon corre-
sponds to a 300-bp fragment that covers the core COL1A1 gene
promoter (200/100 bp).
RESULTS
hc-Krox Increases Type I Collagen Expression in FF, ANF, and
SF—We first studied the effect of hc-Krox on total collagen
synthesis in FF. Cells were transiently transfected with increas-
ing amounts of an expression vector
containing the hc-Krox cDNA, and
the collagen neosynthesis was de-
termined after tritiated proline
labeling. We found that hc-Krox
increased the amount of newly syn-
thesized collagen, which includes
type I isotype as the major form in
the dermis (80% of the total colla-
gen) (Fig. 1A). Western blotting
confirmed that this stimulating
effect did affect type I collagen syn-
thesis, indicating that hc-Krox was
acting as an activator on this protein
production (Fig. 1B).
We then asked whether hc-Krox
was exerting the same effect at the
transcriptional level. To this end,
hc-Krox was overexpressed in FF,
and real time RT-PCR analysis was
performed on total RNA extracts.
hc-Krox always increased moder-
ately COL1A1 mRNA steady-state
levels (Fig. 1C, panel i), whereas it
up-regulated more importantly
COL1A2 (Fig. 1C, panel ii) and
COL3A1 (data not shown) mRNA
steady-state levels. Effective forced
expression of hc-Krox was verified
in FF by measuring the steady-state
levels of its mRNA (Fig. 1C, panel
iii). Similar experiments were per-
formed on ANF to determine
whether hc-Krox regulates type I
collagen expression in this type of
dermal fibroblasts in the same way,
because contradictory data have
been published.
When increased amounts of hc-Krox were overexpressed
in ANF, collagen neosynthesis was also up-regulated, in a
dose-independent manner (Fig. 2A). This activation of total
collagenous protein neosynthesis reflects increased type I
collagen expression, as demonstrated in Western blot anal-
ysis using a specific anti-type I collagen antibody (Fig. 2B).
However, the increase in type I collagen synthesis appeared
relatively weak, as compared with the effect on total collagen
neosynthesis. This could be explained by the fact that West-
ern blot analysis revealed the total collagen produced by the
cells and not only the newly synthesized fraction. Conse-
quently, hc-Krox effect on the neosynthesized fraction could
be underevaluated.
hc-Krox-induced activation of collagen synthesis was
accompaniedwith increasedCOL1A1,COL1A2 (Fig. 2C, panels
i and ii), and COL3A1 (data not shown) mRNA steady-state
levels. Fig. 2C, panel iii, shows that hc-Krox is effectively over-
expressed in ANF after transient transfection.
In this study, we show for the first time that hc-Krox is an
activator of type I collagen expression in normal FF and ANF.
FIGURE 2. hc-Krox increases type I collagen protein synthesis, and COL1A1 and COL1A2mRNAs steady-
state levels inANF.A,ANFwere transfected as in Fig. 1Awith a total amount of DNA equal to 10g. 15 h later,
the culture medium was changed, and a bacterial collagenase assay was realized, as described under “Exper-
imental Procedures.” The values, normalized to total protein amount, are expressed as counts/min/g of
protein and represent themean S.D. of triplicate dishes. B,ANFwere transfected as in A, with a total amount
of DNA of 20 g, and total proteins were extracted and used in Western blotting experiments as described
under “Experimental Procedures” to detect type I procollagen and -actin using specific antibodies. Quantifi-
cationof type I collagenexpressionwasperformedasdescribed in Fig. 1.C,ANFwere transiently transfectedby
the AMAXA Nucleofector with 1 g of pSG5 containing or not the hc-Krox cDNA. 18 h after transfection, total
RNAs were extracted, and 1 g was reverse-transcribed into cDNA. 2 l of cDNAs were diluted 100 times and
used in real time PCR to amplify COL1A1 (panel i), COL1A2 (panel ii), hc-Krox (panel iii), and 18 S cDNAs. COL1A1,
COL1A2, and hc-KroxmRNAs relative expressionwas normalized to 18 S rRNA according to 2Ctmethod (A.U.,
arbitrary units).
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These observations strongly suggest that hc-Krox could be also
implicated in several fibrotic situations, such as scleroderma,
where type I collagen expression is increased.
To elucidate this issue, hc-Krox was overexpressed in adult
SF, and collagen neosynthesis was quantified. As expected,
basal collagen neosynthesis of SF was greater, compared with
ANF (300%) (Fig. 3A compared with Fig. 2A). Fig. 3A shows
that hc-Krox up-regulates collagen neosynthesis, and probably
type I collagen neosynthesis.
To understand if this activating effect is due to a transcrip-
tional regulation, SF were transiently transfected with
increasing amounts of hc-Krox expression vector, and
COL1A1 and COL1A2 mRNA were quantified. Overexpres-
sion of hc-Krox increased mRNA steady-state levels of both
genes (Fig. 3B, panels i and ii), as well as those of COL3A1
(data not shown). hc-Krox was clearly overexpressed in our
experimental system (Fig. 3B, panel iii). These results indi-
cate that hc-Krox is an activator of type I and III collagens
under fibrotic conditions.
hc-KroxUp-regulatesHumanCOL1A1GeneTranscriptional
Activity in FF, ANF, and SF by a Region Located between112
and 61 bp—To investigate the potential hc-Krox effect on
human COL1A1 gene transcription, FF and ANF were tran-
siently transfected with plasmid
constructs covering different re-
gions of human COL1A1 promoter,
in the presence of an expression
vector containing or not the
hc-Krox cDNA. Our data showed
that hc-Krox regulates human
COL1A1 gene in a similar fashion in
both FF and ANF, because in both
cases this transcription factor
up-regulated transcriptional activ-
ity of all constructs tested, except
for the shortest one containing only
61 bp of COL1A1 promoter. There-
fore, hc-Krox effect is mediated by a
sequence located between 112
and61 bp (Fig. 4A, panels i and ii).
Because hc-Krox was earlier
reported as an inhibitor of human
COL1A1 gene expression (16, 17), it
was important to demonstrate that
the activating effect observed in
our study was specifically due to
hc-Krox. Therefore, FF and ANF
were transfected with constructs
containing four copies of the
c-Krox consensus binding site
cloned upstream of the 86 bp of
the mouse Col1a1 short promoter,
containing only the TATA box as a
cis-acting element, which was
associated with the luciferase
reporter gene. hc-Krox specifically
increased the transcription of the
pK1A4Luc construct containing
four copies of the wild-type c-Krox DNA-binding site,
whereas it did not exert any effect on pK1A4mut Luc tran-
scription in which the four copies of the c-Krox-binding site
were mutated (Fig. 4B, panels i and ii). Similar data were
obtained for both FF and ANF and therefore confirm that
hc-Krox is actually a transactivator. Moreover, pK1A4Luc
basal transcriptional activity was higher compared with
pK1A4mut Luc, which means that the endogenous hc-Krox
itself acts as an activator (data not shown).
To determine whether the regulatory mechanisms of type I
collagen expression are the same in SF compared with normal
fibroblasts, the transcriptional function of hc-Krox was deter-
mined, as done in FF and ANF. As shown in Fig. 4C, forced
hc-Krox expression increased transcription of COL1A1
through the 112/61 bp indicating that transcriptional reg-
ulatory mechanisms are similar in ANF and SF.
hc-Krox, Sp1, and CBF Interact Specifically with a Human
COL1A1 Promoter Sequence Located between 112 and 61
bp—Subsequently to the previous data, nucleotide analysis of
the 112/61-bp sequence revealed the presence of one
inverted CCAAT box described previously (101/97 bp
(12)), two GC-rich sequences (93/84 bp, 5 GC-rich box;
80/71 bp, 3 GC-rich box) and one putative hc-Krox bind-
FIGURE 3. hc-Krox increases type I collagen neosynthesis as well as COL1A1 and COL1A2mRNAs steady-
state levels in SF. A, SF were transiently transfected by the calcium phosphate co-precipitation method with
10 g of pSG5 containing or not the hc-Krox cDNA. 15 h later, the cell culture medium was changed, and a
bacterial collagenase assay was carried out, as described under “Experimental Procedures.” The values, nor-
malized to total protein amount, are expressed as counts/min/g of protein and represent themean S.D. of
triplicate dishes. B, SF were transiently transfected by the calcium phosphate co-precipitation procedure with
1 and 5g of pSG5/hc-Krox. For each amount of hc-Krox transfected, the insertless pSG5 vector was used as a
complement to5g, to transfect each samplewith the sameamountofDNA. 15hafter transfection, total RNAs
wereextracted, and1gwas reverse-transcribed into cDNA. 2l of cDNAswerediluted (1:100) andused in real
timePCR to amplifyCOL1A1 (panel i),COL1A2 (panel ii),hc-Krox (panel iii), and 18 S cDNAs.COL1A1,COL1A2, and
hc-Krox mRNAs relative expression was normalized to 18 S rRNA applying the 2Ct method (A.U., arbitrary
units).
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ing site (67/61 bp) (Fig. 5A), which could bind zinc finger
transcription factors such as Sp1, Sp3, and hc-Krox.
To further investigate the interactions between hc-Krox and
DNA in fibroblastic cells, EMSA experiments were performed.
Fig. 5B (and also supplemental Fig. S1) shows that incubation of
the 112/61wt probe (Fig. 5A and Table 2), with nuclear
proteins extracted from FF, produced three major complexes
(1st lane). The slowest migrating correspond to complexes
between DNA and Sp1 and CBF, according to the literature
(43). Additional proof of the presence of Sp1 in the slowest
migrating complex is also provided
by antibody interference experi-
ments (Fig. 6B).
Regarding the faster migrating
complex, it most likely corresponds
to hc-Krox, as demonstrated in Fig.
6A, in which a c-Krox antibody was
used in EMSA experiments. More-
over, this complex has the same
migration profile as hc-Krox com-
plexed to an A1(I)wt oligonucleo-
tide (Table 2 and Fig. 6C), which is
known to bind specifically c-Krox
and was used to clone mc-Krox
(mouse c-Krox) (14 and data not
shown). As we demonstrated previ-
ously, hc-Krox migrates as a dou-
blet, the higher migrating complex
corresponding to hc-Krox mono-
mer and the slower migrating band
to hc-Krox homodimer (14, 15).
In parallel, we analyzed by EMSA
the direct binding of the transcrip-
tion factors to wild-type and
mutated probes with nuclear
extracts from FF and ANF. Fig. 5B
shows that the binding of hc-Krox,
Sp1, and CBF was not modulated
when the 5 GC-rich sequence was
mutated. By contrast, the binding
activity of these transcription fac-
tors was decreased when the 3 GC
box was mutated, indicating that
this region presents more affinity
for these trans factors, compared
with the 5 GC box. A significant
decrease in the binding of hc-Krox,
Sp1, and CBF was observed when
the two GC boxes (112/61mut4),
or only the hc-Krox-binding site
(112/61mut61–62), or only the
CCAAT box (112/61mut3), or
when both the GC-rich sequences
and CCAAT box were mutated
(112/61mut) (Fig. 5B).
Overall, from this EMSA analysis,
it can be concluded that hc-Krox
and Sp1 bind to the 5 and 3 GC
boxes and the67/61 c-Krox sequence. hc-Krox is the factor
that binds with an extremely strong affinity to the 112/
61-bp promoter, compared with Sp1 and CBF. hc-Krox and
Sp1 interact with the three sequences with a decreasing affinity
order as follows:67/61 hc-Krox 3GC box 5GC box.
Moreover, the interaction of CBF with the CCAAT box is
strictly dependent on the presence of functional 5 and 3 GC
boxes as well as the67/61 hc-Krox DNA-binding site. The
binding of c-Krox and Sp1 is also dependent on the binding of
CBF to the CCAAT box.
FIGURE 4.hc-Krox-induced activationof humanCOL1A1gene expression, in FF, ANF, andSF ismediated
by a promoter region located between112 bp and61 bp. A, FF (panel i) and ANF (panel ii) were tran-
siently cotransfected, by the AMAXA Nucleofector method, with 2 g of different COL1A1 (A), pK1A4 Luc or
pK1A4mutLuc (B) reporterplasmids togetherwith1gof thepSV40/-gal expressionvector and1gofpSG5
expression vector containing or not (control) the hc-Krox cDNA. 12 h after transfection, the medium was
changed. 6 h later, the samples were harvested, and protein content, luciferase, and -galactosidase activities
were assayed. Each series of transfectionswasperformed in triplicate. Transcriptional activity of each construct
was expressed as relative luciferase activity (RLU), after correction for both protein amount and transfection
efficiency, and expressed as % versus the respective control transfected with the insertless expression vector
pSG5. Values represent themean S.D. of three independent samples of a representative experiment.ND,not
determined. C, SF were transiently cotransfected and treated as described in A and B with the indicated
reporter constructs. Treatment of the samples and expression of the results are the same as in A.
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Additional EMSA were performed to confirm the identity of
the transcription factors involved in the formation of the differ-
ent complexes (Fig. 6). Nuclear extracts prepared from FF were
incubated in the presence of the radiolabeled 112/61wt
probe and an hc-Krox antibody. In this case, the hc-Krox-DNA
complex formation was abolished (Fig. 6A), and an identical
pattern was observed when nuclear extracts from ANF and SF
were used (data not shown).
When an Sp1 antibodywas added to the binding reaction, the
Sp1-DNA complex also disappeared (Fig. 6B, upper complex),
but it should be noticed that the binding of hc-Krox and CBF to
the probe was decreased, suggesting that Sp1 binding is essen-
tial for the two other transcription factors.
Addition of an Sp3 antibody (Fig. 6B) or an NF-1 antibody
(data not shown) did not modify the interaction pattern of
Sp1, CBF, and hc-Krox to the wild-type probe, suggesting
that this transcription factor does not interact with the
112/61-bp sequence ofCOL1A1 in FF. On the other hand,
in the presence of a CBF antibody, the complex migrating just
below Sp1 disappears, implying that
CBF can bind efficiently on the
112/61-bp region, and again,
when this antibody was used, the
binding of hc-Krox and Sp1 was
slightly decreased, indicating that
CBF facilitates the binding of the
other two zinc finger transcription
factors.
The absence of super-shift in
these assays may be due to the fact
that hc-Krox, Sp1, and CBF anti-
bodies recognize the DNA binding
domain of these transcription fac-
tors, preventing their interaction
withDNA, and therefore the forma-
tion of the complexes.
Finally, additional experiments
were performedwith nuclear extracts
from ANF. As shown in Fig. 6C, hc-
Krox bound on the 112/61
sequence of the COL1A1 promoter
with a stronger activity compared
with Sp1 and CBF. Mutation of both
GCboxesandof theCCAATboxpre-
vented almost all of the binding of
these three transcription factors, as
shown previously in Fig. 5B (Fig. 6C,
panels i and ii, two panels on the left
partof the figure). Sp1 interactedwith
low affinity with the 112/61
COL1A1 sequence compared with a
GC box, present in the first intron
enhancer of the human COL2A1
gene, which binds Sp1 and Sp3
(sequence called enh1 for “enhancer
1”) (38). CBF bound with stronger
affinity to the 112/61 COL1A1
sequence, compared with Sp1 (Fig.
6C, panels i and ii, panel in the right part). Thesedata demonstrate
that the 112/61 sequence of COL1A1 gene binds the same
transcription factors (i.e. hc-Krox, Sp1 and CBF) in FF and ANF.
The Proximal Region of COL1A1 Harbors a Functional
67/61-bp DNA-binding Site for hc-Krox in Dermal
Fibroblasts—Because hc-Krox transactivates human
COL1A1 gene by binding to a sequence located between
112 and 61 bp, we wanted to validate these results in
terms of transcriptional function. For that purpose, we used
the 112/61-bp probe and different mutants as decoy oli-
gonucleotides in transfection experiments. FF were trans-
fected with the pGL2–112-bp construct in the absence of
decoy oligonucleotide or in the presence of a control decoy
oligonucleotide, or the 112/61wt double-stranded
sequence. We found that the 112/61wt decoy oligonu-
cleotide decreased significantly the pGL2–112-bp transcrip-
tional activity, confirming that this region contains activat-
ing cis elements, including binding sites for hc-Krox, Sp1,
and CBF (supplemental Fig. S2).
FIGURE 5. hc-Krox, Sp1, and CBF bind specifically to112/61 bp COL1A1 sequence. DNA binding was
analyzed by EMSA. A, a schematic representation of the112/61-bp region of COL1A1 gene, including the
CCAAT box, the 5 and 3 GC boxes, and the putative hc-Krox-binding site. The different mutant probes in the
112/61-bp sequence used in direct binding EMSAexperiments are presented. Themutations are indicated
in italic and are underlined. B, 5g of FF or ANF nuclear extracts were incubated in direct binding experiments
with the indicated radiolabeled 112/61 wild-type and mutant probes. Arrows indicate the complexes
formed between DNA and nuclear proteins.
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Mutation of both61 and62 nucleotides in the67/61
hc-Krox-binding sitewas able to prevent the inhibition induced
by the112/61wt decoy oligonucleotide, indicating that this
hc-Krox cis element is absolutely critical for the transactivation
potential of this short COL1A1 promoter and for the recruit-
ment of the other activating transcription factors (supplemen-
tal Fig. S2). These data suggest that the integrity of 112/
61-bp promoter region of human COL1A1 gene is crucial for
the preservation of its basal transcriptional activity and that
hc-Krox and Sp1, as well as CBF, are playing the main roles in
this regulatory mechanism.
To examine whether the recognition sites for hc-Krox in
the 112/61-bp region were able to bind specifically the
cognate transcription factor in human fibroblasts and to
effectively modulate transcriptional activity, transient trans-
fections were performed with reporter constructs bearing
mutations in the 3 GC-rich
sequence (112mut73/74) or in
the hc-Krox-binding site located
between67/61-bp (112mut61/
62). As shown in Fig. 7, the
112mut73/74 reporter plasmids
in FF, ANF, and SF displayed a
decreased transcriptional activity
compared with the 112wt reporter
construct, indicating that the 3GC-
rich sequence (71/80-bp site)
binds COL1A1 transactivators (Sp1
and hc-Krox, i.e. Fig. 5B). Mutation
of the 61/67 hc-Krox-binding
site in the 112-bp COL1A1 re-
porter plasmid further decreased
transcription activity indicating
that most part of the hc-Krox func-
tional activity is essentially medi-
ated by the67/61-bp sequence.
However, it should be noticed
that the inhibition percentages
in the 112mut73/74 reporter
constructs compared with their
respective wild-type promoter
plasmids are lowered in SF com-
pared with ANF, and this is also
observed between ANF and FF.
Similar conclusions can be de-
duced concerning the 112mut61/
62 constructs. These data may
suggest that a partial functional
redundancy could take place, and it
is linked to the endogenous levels of
the major COL1A1 transactivators
(i.e. hc-Krox, Sp1, and CBF). In
other words, the effect of the muta-
tions in the 3GC-rich sequence or
in the 61/67 hc-Krox-binding
site can be partly minimized if the
endogenous levels of activators are
higher.
Additionally, the functionality of 67/61-bp hc-Krox
sequence has also been validated in forced hc-Krox expression
experiments in the context of the804-bp COL1A1 promoter
in FF, ANF, and SF (data not shown). These data suggest that
the67/61-bp region is required for the recruitment and full
hc-Krox transactivation potential. All together, these experi-
ments demonstrate that hc-Krox activates the transcription of
COL1A1 gene essentially by the 67/61-bp region of the
gene.
A hc-Krox siRNA Prevents hc-Krox-induced Transactivation
of COL1A1 Gene and Type I Collagen Neosynthesis in FF, ANF,
and SF—To better characterize the transactivating potential of
hc-Krox in fibroblastic cells, the siRNA strategy was used. RNA
interference designed to silence specifically endogenous
hc-Krox expression was used in transient transfection experi-
ments performed in the three fibroblast cell types. Cells were
FIGURE 6.Characterization of the transcription factors that bind to the112/61bpCOL1A1 sequence.
DNAbindingwasanalyzedbyEMSA.AandB,double strand radiolabeled112/61wild-typeoligonucleotide
was incubated with FF nuclear extracts (5 g) in the presence or absence of a c-Krox antibody (5 l), an Sp1
antibody (2 l)), an Sp3 antibody (2 l), or a CBFb-antibody (2 l). C, 5 g of ANF nuclear extracts were
incubated with the indicated labeled double-stranded probes. Enh1 probe represents the2817/2842-bp
sequence of human COL2A1 gene that we previously demonstrated to be highly specific for Sp1/Sp3 (31). This
probe has been used as a positive control to indicate the migration pattern of Sp1. C, panels i and ii, two
exposures of the autoradiograms are presented; on the left a short exposure, and on the right a longer time of
exposure. Arrows indicate the complexes formed between DNA and nuclear proteins.
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first transfected only with a control siRNA or with a hc-Krox
siRNA, and total RNA was extracted, to check hc-Krox siRNA
efficiency on hc-Krox expression and to determine the resulting
effect on COL1A1mRNA steady-state levels and transcription.
Real time RT-PCR analysis revealed a significant decrease of
hc-Krox mRNA steady-state levels in FF, ANF, and SF (50–
85%), which ascertained the siRNA efficiency (Fig. 8,A, panel i,
B, panel i, and C, panel i). Endogenous hc-Krox silencing was
accompanied by an important down-regulation of COL1A1
mRNA steady-state levels (45–85%), providing further evi-
dence for the hc-Krox activating role on COL1A1 gene tran-
scription in the three types of fibroblasts (Fig. 8, A, panel ii, B,
panel ii, and C, panel ii). Next, the three types of fibroblasts
were transfected with the plasmid construct pGL2–112 bp,
which includes the COL1A1 gene domain mediating hc-Krox
effect, in the presence of a control or hc-Krox siRNAs. The data
demonstrate that the hc-Krox siRNA inhibits pGL2–112 bp
transcriptional activity in FF, ANF, and SF, suggesting that hc-
Krox interacts with transactivating cis elements present in the
112/1 bp sequence, through which it induces increased
transcriptional activity of the human COL1A1 gene (Fig. 8, A,
panel iii, B, panel iii, and C, panel iii).
Finally, we determined if the observed effects at the tran-
scriptional level in the hc-Krox knockdown experiments were
also detected at the protein level. For that purpose, FF, ANF,
and SF were transiently transfected with control or hc-Krox
siRNAs, and the collagen neosynthesis was determined. As
shown in Fig. 9, the production of newly synthesized collagens
is decreased by50–65%when an hc-Krox knockdown siRNA
was transfected in the three fibroblastic cell types, confirming
that this transcription factor is an activator of type I collagen
expression. Overall, these data demonstrate that hc-Krox has
the same behavior in FF, ANF, and SF, because the same tran-
scriptional regulatory mechanisms affecting the same target
sequences are involved.
hc-Krox, Sp1, and Sp3 Physically Interact in Primary FF—
Our previous data showed that hc-Krox and Sp1 can bind to the
same COL1A1 promoter region, whose integrity is important
for themaintenance of basal transcriptional activity of the gene.
Knowing that hc-Krox contains a BTB-POZ domain allowing
dimerization and interactions with other transcription factors,
we asked whether hc-Krox could interact physically with Sp1
or/and Sp3 transcription factors. To answer this issue, co-im-
munoprecipitation experiments were performed with nuclear
extracts prepared from FF, using an antibody directed against
c-Krox. Immunoprecipitated proteins were subjected toWest-
ern blotting, and the membranes were incubated with c-Krox,
Sp1, or Sp3 antibodies. Immunoblotting with c-Krox antibody
revealed a band corresponding to a complex of70 kDa, which
matches the hc-Krox apparent molecular weight (67 kDa) and
indicates that hc-Krox was correctly immunoprecipitated (Fig.
10A, panel i). The other two bands of higher electrophoretic
mobility could correspond to - and -hc-Krox homologues.
Similarly, immunoblottings with Sp3 (Fig. 10A, panel ii) and
Sp1 antibodies (Fig. 10A, panel iii) revealed two bands of 85 and
95 kDa corresponding to Sp3 and Sp1 apparent molecular
masses, respectively. These results indicate that Sp3, as well as
Sp1, can interact physically with hc-Krox in primary FF. More-
over, in these experiments, two bands of lower mobility
appeared after treatment with Sp3 antibody; these bands prob-
ably correspond to Sp3 longer isoforms or to Sp family homo-
logues. On the other hand, incubation in the presence of Sp1
antibody produced also two bands migrating less than the
95-kDa band, which could be identified as the Sp1-phosphoryl-
ated form and/or Sp family homologues.
To verify c-Krox antibody specificity, especially with
respect to Sp1, a Western blot experiment was performed.
As presented in Fig. 10B, the c-Krox antibody does not cross-
react with the human recombinant Sp1 protein, therefore
validating the in vivo interaction of hc-Krox and Sp1 as dem-
onstrated in the immunoprecipitation experiments (Fig.
10A, panels i and iii).
To corroborate the above data, protein cross-linking experi-
ments were also carried out. Nuclear extracts prepared from FF
were incubated, in the presence or absence of glutaraldehyde,
and then submitted toWestern blot. After blotting,membranes
were incubated with antibodies against c-Krox, Sp3, and Sp1.
Immunoblotting with c-Krox antibody and without glutar-
aldehyde treatment produced essentially one band of 70 kDa,
corresponding to c-Krox apparent molecular weight (Fig.
10C, panel i). By contrast, in the presence of glutaraldehyde,
the 70-kDa band disappeared, and several bands of lower
electrophoretic mobility were revealed, suggesting that hc-
Krox from FF is involved in multimeric protein complexes
(Fig. 10C, panel i).
Similarly, when an Sp3 antibody was used and in the absence
of cross-linker, two bands corresponding to Sp3 isoforms
appeared (Fig. 10C, panels ii and iii), whereas in the presence of
glutaraldehyde, the intensity of both bands decreased, and
complexes of higher apparent molecular weight appeared.
FIGURE 7.hc-Krox-inducedactivationof humanCOL1A1geneexpression
in FF, ANF, and SF is mediated by the 80/71- and 67/61-bp
sequences. FF, ANF, and SF were transiently cotransfected, by the AMAXA
nucleofector, with 2 g of different COL1A1 reporter plasmids (pGL2-112 bp
wild-type (wt); pGL2–112 bp mutant (mut 73/74); pGL2–112 bp mutant
(mut 61/62)) together with 1 g of the expression vector pSV40/-gal.
12 h after transfection, themediumwas changed. 6 h later, the samples were
harvested, and protein content, luciferase, and -galactosidase activities
were assayed. Each series of transfection was performed in triplicate. Tran-
scriptional activity of each construct was expressed as relative luciferase
activity after correction for both protein amount and transfection efficiency.
Values represent the mean S.D. of three independent samples of a repre-
sentative experiment.
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These data show that Sp3 can also multimerize in FF. Finally,
incubation of the control sample in the presence of an Sp1 anti-
body revealed one band of95 kDa, which corresponds to Sp1
apparent molecular weight. Addition of glutaraldehyde mark-
edly reduced the 95-kDa band intensity and produced a multi-
complex of high molecular weight, showing that Sp1 interacts
with other proteins in FF. These results show that in FF, hc-
Krox, Sp3, and Sp1 form multimeric protein complexes and
interact between each other.
hc-Krox, Sp1, and Sp3 Bind to the COL1A1 Promoter in Vivo—
To determine whether hc-Krox, Sp1, and Sp3 are effectively
involved in the regulation of COL1A1 gene activation, and to
validate our in vitro experimental data, chromatin immunopre-
cipitation assay was performed. As
shown in Fig. 11, these three zinc
finger proteins bind to the200-bp
promoter region of COL1A1 in FF.
These factors could therefore inter-
act and could be recruited on the
same region of COL1A1 gene to
favor optimal transactivation.
The Levels of hc-Krox DNA Bind-
ing Activity Are Correlated with
Type I Collagen Expression in
Fibroblasts—In this study, we show
for the first time that hc-Krox is an
activator of type I collagen expres-
sion in normal and scleroderma
fibroblasts. We next evaluated
whether the endogenous levels of
hc-Krox binding activity could be
correlated with the amounts of type
I collagen produced by fibroblasts.
Thus, we compared side by side the
endogenous expression of type I
collagen (steady-state mRNA, pro-
tein levels, and transcriptional
activity) in FF, ANF, and SF, as well
as the corresponding hc-Krox bind-
ing activity on the COL1A1 112/
61 bp promoter. As shown in Fig.
12A, the hc-Krox binding activity is
higher in SF compared with ANF,
which also present a much more
higher DNA binding activity com-
pared with FF. Collagen neosynthe-
sis evaluated in parallel on the same
cells was shown to be approximately
3- and 4-fold higher in SF compared
to ANF and FF, respectively (Fig.
12B). These observed effects on type
I collagen expression resulted from
a transcriptional control because
the transcription of the pGL2–
112-bp COL1A1 construct is higher
in SF compared with ANF, and also
increased inANF comparedwith FF
(Fig. 12C). These transcriptional
effects were also confirmed at the level of COL1A1, COL1A2,
andCOL3A1 steady-statemRNAamounts (supplemental Fig. S3).
It can be concluded that hc-Krox activates type I collagen
expression in dermal fibroblasts, and the DNA binding activity
of this transcription factor determines, at least in part, the levels
of the endogenous type I collagen expression. Knowing that
increased collagen synthesis is amajor event observed in sclero-
derma, we may assume that hc-Krox is one of the transcription
factors involved in the COL1A1 up-regulation.
DISCUSSION
This study focuses on molecular mechanisms controlling
human COL1A1 gene transcription in physiopathological con-
FIGURE8.hc-Krox siRNA inhibits thehc-Krox-inducedactivationof type I collagenexpression inFF,ANF,
and SF. A–C, FF (A), ANF (B), and SF (C) were transiently transfected by the AMAXA nucleofector with 1 g of a
control or hc-Krox siRNA. 12 h after transfection, the cell culture mediumwas changed, and 6 h later, the samples
were harvested. 1g of total RNAs extractedwas reverse-transcribed into cDNA. 2l of cDNAwere diluted (1:100)
and used in real time PCR to amplify hc-Krox (A, panel i; B, panel i; and C, panel i), COL1A1 (A, panel ii; B, panel ii; and
C, panel ii), and 18 S cDNAs. The relative expression of hc-Krox and COL1A1 mRNAs was normalized to 18 S rRNA
according to 2Ct method (A.U., arbitrary units). In parallel, fibroblasts were transiently transfected using the
AMAXAnucleofectorwithacontrolorahc-KroxsiRNA(1g) togetherwith2gofpGL2-112-bpconstructand1g
of the expression vector pSV40/-gal. 12 h after transfection, themediumwas replaced. 6 h later, the sampleswere
harvested, and transcriptional activities have been analyzed as described in Fig. 4.
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ditions. We particularly investigated the role of hc-Krox
transcription factor in human adult and foreskin (from chil-
dren) normal fibroblasts and in scleroderma fibroblasts. This
approach should later on facilitate the clarification of events
potentially implicated in the manifestation and/or evolution
of the fibrotic reaction. Our results showed that hc-Krox is
able to activate type I collagen expression, at the protein,
transcriptional, and gene activity levels, in all types of pri-
mary fibroblastic cells. The data also demonstrate that this
transcription factor interacts physically with Sp1 and Sp3
and that each of these trans factors binds in vivo on the core
promoter of COL1A1.
Our particular interest for hc-Krox function in human skin
fibroblasts comes from the fact that this factor has been
described previously as an inhibitor of type I collagen expres-
sion in NIH-3T3 mouse fibroblastic cells (16). These data sug-
gested that hc-Krox could be involved in the fibrotic process
and make it a motivating target to better understand sclero-
derma. The present results revealed in fact that hc-Krox is a
potent activator of type I collagen expression in normal foreskin
and adult fibroblasts but also in scleroderma cells. The discrep-
ancy between our study and previous results can be due to the
cell type and/or to different experimental procedures used. For
example, the transfection method employed here is the Amaxa
nucleofection, which is, in our hands, the more appropriate
method to obtain high transfection efficiency and proper expres-
sion of the reporter gene, especially for high size reporter vectors.
FIGURE 9. hc-Krox siRNA inhibits the hc-Krox-induced increase of type I
collagen neosynthesis in FF, ANF, and SF. FF, ANF, and SF were transiently
transfected by the AMAXA nucleofector with 1 g of a control or of hc-Krox
siRNA. 12 h after transfection, the cell culture medium was replaced, and
the cells were incubated in the same fresh medium supplemented with
-aminopropionitrile (50g/ml) and ascorbic acid (50g/ml) for a further
24-h period. The same medium was then renewed, and [3H]proline (2
Ci/ml) was added. After 24 h, the culture medium was collected and the
labeled collagen was assayed, using the bacterial collagenase method.
The values, normalized to total protein amount, are expressed as counts/
min/g of protein and represent the mean  S.D. of triplicate dishes.
FIGURE 10. hc-Krox, Sp1, and Sp3 interact physically in FF. A, hc-Krox was
immunoprecipitated (IP) in total cellular extracts prepared from 2.5 106 FF.
Proteins isolated after immunoprecipitation were denatured and separated
by SDS-PAGE. Three samples were transferred to polyvinylidene difluoride
membranes and reacted with polyclonal antibodies against hc-Krox (panel i),
Sp3 (panel ii), and Sp1 (panel iii). Proteins were revealed with a peroxidase-
coupled secondary antibody (anti-rabbit IgG) using a West-Pico Western
detection kit.Arrows indicate themolecularweight of proteins recognized by
antibodies, as estimated by prestained marker proteins. B, 1 l of human
recombinant Sp1 protein (Promega) was separated by SDS-PAGE. The sam-
ples were then transferred to polyvinylidene difluoride membranes, which
were reactedwith polyclonal antibodies directed against hc-Krox (1:100 dilu-
tion) and Sp1 (1:300 dilution). Protein was revealed with a peroxidase-cou-
pled secondary antibody (anti-rabbit IgG) using a West-Pico Western detec-
tion kit. C, 10g of FF nuclear extracts were incubatedwith or without 2l of
glutaraldehyde0.1%, during 10min at room temperature. Proteinswere then
denaturated and separated by SDS-PAGE. Samples were transferred to poly-
vinylidene difluoride membranes and reacted with antibodies against hc-
Krox (panel i), Sp3 (panels ii and iii), and Sp1 (panel iv). Proteins were revealed
as in A. Arrows indicate the molecular weight of proteins recognized by anti-
bodies, as estimated by prestained marker proteins. Panel iii represents a
shorter film exposure as compared with ii.
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hc-Krox inhibiting effects have been associated to its BTB/
POZ domain. In the case of promyelotic leukemia zinc finger,
the BTB/POZ domain is located at the N-terminal extremity
and interacts with co-repressors, like silencing mediator for
retinoid and thyroid hormone receptors, and nuclear receptor
co-repressor. Co-repressors recruit histone deacetylase 1 that
interacts with the target promoter and inhibits its transcrip-
tional activity, modifying locally the chromatin structure (44).
However, all transcription factors carrying BTB/POZ domains
are not trans-repressors. For example,Drosophila CAGA tran-
scription factor, encoded by Trithorax-like gene, enhances
transcription activity by preventing chromatin condensation.
In this case, the BTB/POZ domain provokes the oligomeriza-
tion of CAGA factor, and this structure allows direct interac-
tion with many sites of DNA to the detriment of the nucleo-
some structure in a way that makes the promoter accessible to
transactivators (45).
Moreover, it is not very surprising that hc-Krox behaves as an
activator of collagen in skin fibroblasts because we demon-
strated that its mouse homologue, mc-Krox, is an activator of
mouse Col1a1 gene in NIH-3T3 fibroblasts (14). Additionally,
we showed that mc-Krox is highly expressed in skin and that its
expression during development precedes at least 3 days type I col-
lagen expression (14). This element strongly suggests that c-Krox
is a factor that could initiate and enhance type I collagen synthesis.
Even if the mc-Krox cDNA at that time was an incomplete
clone lacking the BTB/POZ domain, we have shown that the
transactivating effects exerted on target gene transcription
were mediated by its C-terminal extremity and the zinc finger
domain (15). This is in agreement with the observations of
Widom et al. (16), who showed that the truncation of hc-Krox
N-terminal domain (but not of BTB/POZ domain alone) leads
to an activation of target genes transcription, thus preventing
the inhibiting effect.
Currently, no identified mechanism characterizing c-Krox
function is known. Nevertheless, an interesting example of
transcription factors having a dual activation or repression
domain has been reported for YY1 (“Yin Yang-1”), another
Kru¨ppel-like factor. Thus, YY1 can activate or inhibit target
gene transcription depending on its relative concentration,
of the promoter, and/or of the cellular context (46–49). The
mechanism proposed to explain its bifunctional effect is
related to the interaction of the factor with histone acetyl-
transferases, such as CBP, p300, and PCAF (CBP/p300 asso-
ciated factor) and histone deacetylases 1-, -2, and -3 (50, 51).
These findings, together with the capacity of YY1 to interact
with Sp1, GATA-1, and c-Myc (52, 53) suggest an hypothesis
for hc-Krox function.
This hypothesis could be supported by the fact that c-Krox
can homo- or heterodimerize through its BTB/POZ or C-ter-
minal domains (15, 17). Although the proteins interacting with
this factor are not yet all identified, it seems very plausible that
the transactivating effects of hc-Krox could depend on the spa-
tial configuration of the protein, on the promoter sequences
surrounding c-Krox-binding sites and, on the context of the
transcriptional partner.
FIGURE 11. hc-Krox, Sp1, and Sp3 bind in vivo to the COL1A1 promoter.
Ten flasks of FF cultures were fixed, digested, and immunoprecipitated over-
night by hc-Krox, Sp1, and Sp3 antibodies. These steps were followed by PCR
amplification with primers flanking the112/61 sequence of the COL1A1
promoter. As positive control (Input), the same primers were used on the
genomic DNA. Samples were also immunoprecipitated with anti-RNA poly-
merase II used as positive control (C) and with a nonspecific immunoglob-
ulin used as a negative control (C).
FIGURE 12. The endogenous hc-Krox DNA binding activity to COL1A1
gene in fibroblasts is correlated with type I collagen synthesis. A, DNA
binding was analyzed by EMSA. 7.5 g of FF or ANF or SF nuclear extracts
were incubated with the radiolabeled 112/61 wild-type probe, in direct
binding experiments. Arrow indicates the complexes formed between DNA
and hc-Krox. B, confluent cultures of FF, ANF, and SF were preincubated for
24 h in Dulbecco’s modified Eagle’s medium 10% fetal calf serum supple-
mented with -aminopropionitrile (50 g/ml) and ascorbic acid (50 g/ml).
The samemediumwas then renewed, and [3H]Proline (2Ci/ml) was added.
After 24 h, the cell culture medium was collected, and the labeled collagen
was assayed, using the bacterial collagenase method, as described under
“Experimental Procedures.” The values, normalized to total protein amount,
are expressed as counts/min/g of protein and represent themean S.D. of
triplicate dishes. C, FF, ANF, and SF were transiently transfected using the
AMAXA nucleofector with 2 g of pGL2–112-bp construct and 1 g of the
expression vector pSV40/-gal. 12 h after transfection, the medium was
replaced. 6 h later, the samples were harvested, and transcriptional activities
have been analyzed as described in Fig. 4.
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Indeed, previous results showed that hc-Krox inhibits human
COL2A1 and UGDH genes transcriptional activity in differenti-
ated and de-differentiated rabbit articular chondrocytes by bind-
ing close to Sp1/3-binding sites (18, 38),6 whereas it activates the
human COL1A1 gene in skin fibroblasts by interacting with Sp1
andSp3 (this paper). Thus, at the same timehc-Krox seems tobe a
pro-arthrotic and a pro-fibrotic factor, suggesting its involvement
in inflammatory or/and immune responses.
It has been shown recently that the full-lengthmc-Krox plays
a key role in the differentiation of thymocytes in CD4 helper
rather than in CD8 killer T lymphocytes (19, 20). Constitutive
expression of c-Krox in helper-deficient mice led to the differ-
entiation of class I-restricted thymocytes in CD4 cells,
whereas overexpression of a mutant form of this transcription
factor appeared functionally inert (20). Interestingly, during the
first stages of scleroderma disease, an accumulation of CD4
lymphocytes is observed, whereas CD8 population is
decreased. CD4 cells migrate in vascular epithelium and der-
mis connective tissues and lead to an activation of target cells
and to an increased production of pro-fibrogenic growth fac-
tors and cytokines (22, 54). Taken together, these data suggest
that hc-Krox could be one of the first actors involved in the
manifestation of scleroderma, playing a role in the immune
reaction but also in the remodeling of dermis ECM.
This study provides some evidence about this last issue,
because hc-Krox was found to increase COL1A1 transcrip-
tional activity and not only COL1A1, COL1A2, and COL3A1
mRNA steady-state levels but also Sp1 and Sp3 transcription
(data not shown), two other activators of type I collagen genes
(6, 10, 11, 28, data not shown). These three zinc finger factors
interact with the same human COL1A1 promoter region as
demonstrated in chromatin immunoprecipitation experi-
ments, through which they exert their activating effects (this
study and data not shown). Artlett et al. (55) showed that this
region is sufficient to confer maximal transcriptional activity of
the human COL1A1 gene in vitro. From a transcriptional point
of view, nucleotide analysis of the 198-bp sequence revealed
four potential binding sites for hc-Krox (168/141,
93/84, 80/71, and 54/47 bp), all of them overlap-
ping with Sp1/Sp3 potential binding sites. EMSA experiments
showed that hc-Krox can bind with high affinity to 168/
141- and80/71-bp sequences, whereas its affinity for the
other two sites is very low (data not shown). However, from our
EMSA analysis and transient transfection assays, we have iden-
tified a new 67/61-bp sequence binding hc-Krox that
clearly mediates a great part of its activating effect in FF, ANF,
and SF.
Our data also demonstrate that in terms of binding affinity
and amount, hc-Krox is themajor transcription factor interact-
ing with the 112/61-bp region, compared with CBF and
Sp1. Moreover, as demonstrated by Cicchillitti et al. (43), we
confirmed that Sp1 and CBF interact with this sequence, and
the latter one binds much more efficiently compared with Sp1.
CBF interacts with the 100/96-bp sequence, enhancing
COL1A1 transcriptional activity, providing further evidence
that the198/1-bp proximal promoter, and particularly the
112/61-bp sequence, plays a critical role in the regulation of
human COL1A1 gene in human skin fibroblasts. Besides, it is
noteworthy that the binding of each factor is dependent of the
binding of the others.
In this sense, transient transfections were performed with
reporter constructs bearing mutations in the 3 GC-rich
sequence or in the hc-Krox-binding site located between67/
61 bp. The data revealed that the extent of inhibition in the
mutated reporter constructs compared with their respective
wild-type promoter plasmids is lower in SF compared with
ANF, and this effect is even more pronounced when compared
with FF. We therefore hypothesize that a partial functional
redundancy could be effective, and this is probably because of
the fact that endogenous levels of the major COL1A1 transac-
tivators such as hc-Krox, Sp1, and CBF display a greater DNA
binding activity in SF compared with the normal fibroblasts.
This means that the effect of the mutations in the 3 GC-rich
sequence or in the 61/67 bp hc-Krox-binding site can be
partly counteracted if the endogenous levels of activators are
higher.
Additionally, our results are in agreement with those
obtained by Hitraya et al. (56) who reported that the maxi-
mal transcriptional activity of COL1A1 is located within the
129- and84-bp region. This region includes two tandem
NF1/Sp1 elements (129/107-bp and 104/78-bp) and
the CCAAT-box, and the cognate transcription factors dis-
play a higher binding activity in nuclear extracts from SSc
fibroblasts (12, 56). We demonstrate here that hc-Krox also
appears to have a pivotal role in the activated expression of
COL1A1 in SSc fibroblasts, because its DNA binding activity
is increased in SF nuclear extracts in comparison with the
nuclear extracts from normal cells (ANF and FF). Moreover,
our observations suggest that hc-Krox is involved in both
basal and increased COL1A1 transcription and that the level
of hc-Krox DNA binding activity is closely correlated with
the type I collagen expression in fibroblasts, as demonstrated
for Sp1 and CBF (12, 56).
To explain that the 112/61-bp sequence binds mainly
hc-Krox in our EMSA, and to a much more lower extent CBF
and Sp1, we propose that our probe covers the oligonucleotidic
sequence between 78 to 61 bp in which we have identified
for the first time a new hc-Krox DNA-binding element (i.e.
67/61 bp), which is responsible for the main part of the
transactivating effect of this factor as demonstrated in
mutagenesis functional assays (Fig. 7). By contrast, other stud-
ies have restricted their analysis to the 104/78-bp region
and have not focused on the downstream sequences.
Taken together, these data suggest that, in human skin fibro-
blasts, the112/61-bp regionmay interact with several tran-
scription factors exerting activating effects on human COL1A1
gene transcription, but also promoting interactionswithTATA
box and/or other promoter or intron sequences of the gene.
In conclusion, we have characterized the transcriptional
function of hc-Krox on human COL1A1 gene in healthy fore-
skin fibroblasts and correlated these findings with data
obtained in adult normal and scleroderma fibroblasts. Given
the relatively tissue-restricted expression of hc-Krox compared6 B. Pore´e, E. Renard, G. Beauchef, and P. Gale´ra, unpublished observations.
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with Sp1 and CBF, all these data make this factor an attractive
candidate for setting up therapeutic strategies against fibrotic
diseases. Additionally, we showed for the first time that hc-
Krox is able to form macromolecular complexes with other
transcription factors such as Sp1 and Sp3. This element, asso-
ciated with the fact that all three factors exert their transacti-
vating effects through a COL1A1 198-bp short promoter, will
allow us to develop further analysis of human COL1A1 gene
regulation of expression, taking into account the complexity of
molecular mechanisms controlled by direct or indirect interac-
tions between endogenous nuclear factors under normal and
pathological conditions.
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Figure S1.  hc-Krox, Sp1, and CBF bind specifically to -112/-61 bp COL1A1 sequence. 
DNA binding was analyzed by EMSA.  
Panel A.i – A double-strand radiolabeled -112/-61 wt oligonucleotide was incubated with FF 
nuclear extracts (5 µg) (lanes 2-13) or with human recombinant Sp1 protein (Promega, 
Charbonnières, France) (lane 14). Competition with molar excesses of cold wild-type and 
mutant oligonucleotides were performed (-112/-61wt: lanes 3-4, -112/-61mut: lanes 5-6, -
112/-61mut1: lanes 7-9, -112/-61mut2: lanes 10-11, -112/-61mut3: lanes 12-13). Lane 1 
represents the probe incubated without nuclear extracts. Panel A.ii represents a magnification 
of C1 and C2 complexes corresponding respectively to Sp1 and CBF. Panel B – 5 µg of FF 
nuclear extracts were incubated with a double-strand labeled -112/-61 wt oligonucleotide 
(lanes 1-6) in the presence of molar excesses of cold wild-type and mutant oligonucleotides (-
112/-61wt (lanes 2-3), -112/-61mut4 (lanes 4-6)). Arrows indicate the complexes formed 
between DNA and nuclear proteins. 
 
Fig. S1Ai shows that incubation of the -112/-61wt probe (Table I) with nuclear proteins 
extracted from FF, revealed two major complexes (lane 2). The slowest migrating two bands, 
called C1 and C2, are magnified in Fig. S1Aii, and correspond, according to the literature 
(43), to complexes between DNA and Sp1 (C1) or CBF (C2). To get more information about 
the identity of the C1 complex, the same oligonucleotide was incubated with the human 
recombinant Sp1 protein (lane 14) and only one complex, having an identical migration 
profile as C1, was detected. These data provide further evidence that C1 corresponds to Sp1. 
Another proof of the presence of Sp1 in C1 complex was also provided by antibody 
interference experiments (Fig. 6B). 
The binding specificity of these two complexes (C1 and C2) was studied in competition 
experiments, using wild-type and mutated oligonucleotides presented in Table I and Fig. 5A. 
Thus, competition with an unlabeled -112/-61wt oligonucleotide decreased the binding of 
both complexes (lanes 3, 4), suggesting the specificity of the interactions observed between 
proteins and DNA. When the -112/-61mut was used as a cold competitor, in which  both GC-
rich sequences and the CCAAT box were mutated, a decrease of the binding activity of Sp1, 
CBF and hc-Krox to the probe was found (lanes 5, 6). This finding indicates that another cis 
element is able to bind or recruit the three transcription factors in the -112/-61-bp region. The 
data provide further evidence that mutation of the three boxes present on -112/-61 bp 
COL1A1 sequence is not sufficient to prevent the binding of proteins interacting with the wild 
type sequence. Additionally, when the 5’ GC-rich box was mutated (-112/-61mut1) and used 
as a competitor (lanes 7-9), the formation of Sp1/CBF-DNA and hc-Krox-DNA complexes 
was reduced, demonstrating that the transcription factors are still able to directly interact with 
the inverted CCAAT box and the 3’ GC-rich box which are not mutated, as well as with other 
domains of the -112/-61 bp sequence located in 3’.  
Mutation only in the 3’ GC-rich box (-112/-61mut2) competed efficiently the binding of 
Sp1, CBF and hc-Krox to the probe (lanes 10, 11). This suggests that an interaction of Sp1 
and hc-Krox with the 5’ GC-rich and with the putative hc-Krox cis element (-67/-61) is 
possible. When a cold competitor mutated only in  the CCAAT box was used, it significantly 
reduced the binding of the three transcription factors (lanes 12, 13). The observation of lanes 
12, and 13 reveals a significant decrease of the C2 complex (which corresponds to CBF), that 
normally should not be altered, and strongly suggests that CBF needs to interact with factors 
binding to the GC-rich boxes in order to bind efficiently on COL1A1 promoter. Finally, 
competition with a -112/-61mut4 oligonucleotide, in which both GC-rich sequences were 
mutated, was able to slightly compete away the binding of hc-Krox, Sp1 and CBF to the wild-
type probe, confirming that these transcription factors can be recruited probably through the -
67/-61 hc-Krox site (Fig. S1B). 
 
Figure S2. Decoy oligonucleotides corresponding to -112/-61 bp promoter region of 
COL1A1 gene are able to reverse hc-Krox transactivating effect. 
Panels A, B and C - FF were transiently transfected by the AMAXA nucleofector with 2 µg of 
pGL2-112 bp construct and 1 µg of the expression vector pSV40/β-gal. 30 µg of different 
oligonucleotides corresponding to the wild type -112/-61 bp sequence or mutant derivatives 
(indicated on the Fig.) were added in the culture medium immediately after transfection. 12 
hrs after transfection, the medium was changed and supplemented with the same decoy 
oligonucleotide (30 µg). 6 hrs later, cells were harvested and relative transcriptional activities 
have been analyzed.  
 
Having shown that hc-Krox can transactivate human COL1A1 gene by binding to a 
sequence located between -112 and -61 bp, we tried to validate these results in terms of 
transcriptional function. We used the -112/-61 bp probe and different mutants as decoy 
oligonucleotides in transfection experiments. FF were transfected with the pGL2-112 bp 
construct in the absence of decoy oligonucleotide or in the presence of a control decoy 
oligonucleotide (a sequence of the human COL2A1 intronic enhancer binding specifically 
SOX9 transcription factor), or the -112/-61wt double-stranded sequence. We found that the -
112/-61wt decoy oligonucleotide decreased significantly the pGL2-112 bp transcriptional 
activity, confirming that this region contains activating cis elements, including binding sites 
for hc-Krox, Sp1, and CBF (Fig. S2A). To determine the possible involvement of the 5’ and 
3’ GC-rich sequences and the CCAAT box in the transcription activity of the -112 bp 
COL1A1 promoter, several mutants were used. As shown in Fig. S2A, transfection of a decoy 
oligonucleotide presenting a mutation in both 5’ and 3’ GC boxes, together with a mutation in 
the CCAAT box, allowed to maintain almost all of the basal transcription activity of the -112-
bp COL1A1 promoter, demonstrating that hc-Krox and Sp1 bind to the two GC boxes and 
CBF to the CCAAT sequence, and that all are transactivators.  
In Fig. S2B, a hc-Krox consensus oligonucleotide (DAα1(I)wt), used as a decoy, inhibited 
the transcription of the pGL2-112 bp construct, confirming again that hc-Krox is an activator 
of COL1A1 transcription. In this set of experiments, -112/-61 bp mutants were also used as 
competitors. D-112/-61mut1 (for decoy -112/-61 bp mut1, mutation in the 5’ GC-rich 
sequence), which competes for CBF and partially for Sp1 and hc-Krox binding, slightly 
reduced the 112 bp promoter activity, suggesting that Sp1 and hc-Krox still bind respectively 
on the 5’-GC-rich and the hc-Krox regions, and are sufficient to maintain almost all the basal 
transcriptional activity of the promoter. However, D-112/-61mut2 (mutation only in the 3’ 
GC-rich sequence) and D-112/-61mut3 (mutation in the CCAAT box) induced a greater 
decrease of the 112 bp promoter activity. These data demonstrate that the integrity of the 5’ 
and 3’ GC-rich sequence, but also the -67/-61 cis element and the CCAAT box are important 
for the maintenance of the basal activity of the promoter. Moreover these results are in 
agreement with our EMSA results which show that hc-Krox, Sp1 and CBF bind on the -112/-
61 bp sequence in an interdependent way, and prove that all of them are activators of the 
COL1A1 gene transcription. Moreover, the use of -112/-61mut4 decoy, which allowed a very 
weak Sp1 and hc-Krox binding to the promoter, abrogating CBF fixation and inducing a 
down-regulation of promoter activity comes as a further support to our previous findings 
according to which hc-Krox, Sp1 and CBF binding on -112/-61 bp sequence is 
interdependent. 
Mutation of both -61 and -62 nucleotides in the -67/-61 hc-Krox binding site was able to 
prevent the inhibition induced by the -112/-61wt decoy oligonucleotide, indicating that this 
hc-Krox cis element is absolutely critical for the transactivation potential of this short 
COL1A1 promoter and for the recruitment of the other activating transcription factors (Fig. 
S2C). The same decoy strategy was also applied to ANF and similar data were obtained when 
-112/-61wt, -112/-61mut, and -112/-61mut-61-62 sequences were used as decoy 
oligonucleotides (data not shown). 
These data suggest that the integrity of -112/-61 bp promoter region of human COL1A1 
gene is crucial for the preservation of its basal transcriptional activity and that hc-Krox and 
Sp1, as well as CBF, are playing the main roles in this regulatory mechanism. 
 
Figure S3. The hc-Krox endogenous DNA-binding activity to COL1A1 gene in 
fibroblasts is correlated with type I collagen synthesis. 
Total RNAs were extracted from FF, ANF, and SF cultures. 1 µg of total RNAs was reverse-
transcribed into cDNA. 2 µl of cDNAs were diluted 100 times and used in real time PCR to 
amplify COL1A1 (panel A), COL1A2 (panel B), COL3A1 (panel C) and GAPDH cDNAs, 
with specific forward and reverse primers. COL1A1, COL1A2, and COL3A1 mRNAs relative 
expression was normalized to GAPDH mRNA according to 2-deltaCT method (A.U. Arbitrary 
Units). 
 The results indicate that SF express higher amounts of COL1A1, COL1A2, and 
COL3A1 mRNA compared to ANF. The same conclusion is also true for ANF compared to 
FF. 
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